Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574288 · ClinicalTrials.gov registry record · Phase 2
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT00574288 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 104 participants.
The verdict
NCT00574288, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
Establishment of safety profile of HuMax-CD38 when given as monotherapy in participants with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment options.
Interventions
- DRUG Part 1: Daratumumab
- DRUG Part 2: Daratumumab
- OTHER Methylprednisolone
- OTHER Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2008-03-26 |
| Est. Completion | 2017-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574288
The ClinicalTrials.gov registry entry for NCT00574288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Part 1: Daratumumab is the first listed.
NCT00574288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574288 about?
NCT00574288 is a clinical study titled "Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma". Establishment of safety profile of HuMax-CD38 when given as monotherapy in participants with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment options.
What is the current status of trial NCT00574288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2008-03-26. Estimated completion is 2017-04-03.
What interventions are being tested in trial NCT00574288?
The interventions under investigation include: Part 1: Daratumumab (DRUG), Part 2: Daratumumab (DRUG), Methylprednisolone (OTHER), Dexamethasone (OTHER).
Who is sponsoring clinical trial NCT00574288?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.